Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes

Objective: As gene-based therapies may soon arise for patients with spinocerebellar ataxia (SCA), there is a critical need to identify biomarkers of disease progression with effect sizes greater than clinical scores, enabling trials with smaller sample sizes. Methods: We enrolled a unique cohort of...

Full description

Bibliographic Details
Main Authors: Isaac M. Adanyeguh, Vincent Perlbarg, Pierre-Gilles Henry, Daisy Rinaldi, Elodie Petit, Romain Valabregue, Alexis Brice, Alexandra Durr, Fanny Mochel
Format: Article
Language:English
Published: Elsevier 2018-01-01
Series:NeuroImage: Clinical
Online Access:http://www.sciencedirect.com/science/article/pii/S2213158218301943
id doaj-a98f9f436c4249948524b4f7c0ddd367
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Isaac M. Adanyeguh
Vincent Perlbarg
Pierre-Gilles Henry
Daisy Rinaldi
Elodie Petit
Romain Valabregue
Alexis Brice
Alexandra Durr
Fanny Mochel
spellingShingle Isaac M. Adanyeguh
Vincent Perlbarg
Pierre-Gilles Henry
Daisy Rinaldi
Elodie Petit
Romain Valabregue
Alexis Brice
Alexandra Durr
Fanny Mochel
Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
NeuroImage: Clinical
author_facet Isaac M. Adanyeguh
Vincent Perlbarg
Pierre-Gilles Henry
Daisy Rinaldi
Elodie Petit
Romain Valabregue
Alexis Brice
Alexandra Durr
Fanny Mochel
author_sort Isaac M. Adanyeguh
title Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
title_short Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
title_full Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
title_fullStr Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
title_full_unstemmed Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes
title_sort autosomal dominant cerebellar ataxias: imaging biomarkers with high effect sizes
publisher Elsevier
series NeuroImage: Clinical
issn 2213-1582
publishDate 2018-01-01
description Objective: As gene-based therapies may soon arise for patients with spinocerebellar ataxia (SCA), there is a critical need to identify biomarkers of disease progression with effect sizes greater than clinical scores, enabling trials with smaller sample sizes. Methods: We enrolled a unique cohort of patients with SCA1 (n = 15), SCA2 (n = 12), SCA3 (n = 20) and SCA7 (n = 10) and 24 healthy controls of similar age, sex and body mass index. We collected longitudinal clinical and imaging data at baseline and follow-up (mean interval of 24 months). We performed both manual and automated volumetric analyses. Diffusion tensor imaging (DTI) and a novel tractography method, called fixel-based analysis (FBA), were assessed at follow-up. Effect sizes were calculated for clinical scores and imaging parameters. Results: Clinical scores worsened as atrophy increased over time (p < 0.05). However, atrophy of cerebellum and pons showed very large effect sizes (>1.2) compared to clinical scores (<0.8). FBA, applied for the first time to SCA, was sensitive to microstructural cross-sectional differences that were not captured by conventional DTI metrics, especially in the less studied SCA7 group. FBA also showed larger effect sizes than DTI metrics. Conclusion: This study showed that volumetry outperformed clinical scores to measure disease progression in SCA1, SCA2, SCA3 and SCA7. Therefore, we advocate the use of volumetric biomarkers in therapeutic trials of autosomal dominant ataxias. In addition, FBA showed larger effect size than DTI to detect cross-sectional microstructural alterations in patients relative to controls. Keywords: Spinocerebellar ataxia, Imaging biomarkers, Apparent fiber density, Fixel analysis, Diffusion imaging.
url http://www.sciencedirect.com/science/article/pii/S2213158218301943
work_keys_str_mv AT isaacmadanyeguh autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT vincentperlbarg autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT pierregilleshenry autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT daisyrinaldi autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT elodiepetit autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT romainvalabregue autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT alexisbrice autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT alexandradurr autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
AT fannymochel autosomaldominantcerebellarataxiasimagingbiomarkerswithhigheffectsizes
_version_ 1725416120430624768
spelling doaj-a98f9f436c4249948524b4f7c0ddd3672020-11-25T00:08:13ZengElsevierNeuroImage: Clinical2213-15822018-01-0119858867Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizesIsaac M. Adanyeguh0Vincent Perlbarg1Pierre-Gilles Henry2Daisy Rinaldi3Elodie Petit4Romain Valabregue5Alexis Brice6Alexandra Durr7Fanny Mochel8INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, FranceINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France; Bioinformatics and Biostatistics Core Facililty, iCONICS, Institut du Ceveau et de la Moelle épinière, ICM, F-75013 Paris, FranceCenter for Magnetic Resonance Research (CMRR), University of Minnesota, Minneapolis, MN, United StatesINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, FranceINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, FranceINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France; Center for NeuroImaging Research (CENIR), Institut du Cerveau et de la Moelle épinière, 75013 Paris, FranceINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, FranceINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France; AP-HP, Pitié-Salpêtrière University Hospital, Department of Genetics, Paris, FranceINSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, F-75013 Paris, France; AP-HP, Pitié-Salpêtrière University Hospital, Department of Genetics, Paris, France; University Pierre and Marie Curie, Neurometabolic Research Group, Paris, France; Corresponding author at: Reference Center for Neurometabolic Diseases, Department of Genetics, La Pitié-Salpêtrière University Hospital, 47 Boulevard de l'Hôpital, 75013 Paris, France.Objective: As gene-based therapies may soon arise for patients with spinocerebellar ataxia (SCA), there is a critical need to identify biomarkers of disease progression with effect sizes greater than clinical scores, enabling trials with smaller sample sizes. Methods: We enrolled a unique cohort of patients with SCA1 (n = 15), SCA2 (n = 12), SCA3 (n = 20) and SCA7 (n = 10) and 24 healthy controls of similar age, sex and body mass index. We collected longitudinal clinical and imaging data at baseline and follow-up (mean interval of 24 months). We performed both manual and automated volumetric analyses. Diffusion tensor imaging (DTI) and a novel tractography method, called fixel-based analysis (FBA), were assessed at follow-up. Effect sizes were calculated for clinical scores and imaging parameters. Results: Clinical scores worsened as atrophy increased over time (p < 0.05). However, atrophy of cerebellum and pons showed very large effect sizes (>1.2) compared to clinical scores (<0.8). FBA, applied for the first time to SCA, was sensitive to microstructural cross-sectional differences that were not captured by conventional DTI metrics, especially in the less studied SCA7 group. FBA also showed larger effect sizes than DTI metrics. Conclusion: This study showed that volumetry outperformed clinical scores to measure disease progression in SCA1, SCA2, SCA3 and SCA7. Therefore, we advocate the use of volumetric biomarkers in therapeutic trials of autosomal dominant ataxias. In addition, FBA showed larger effect size than DTI to detect cross-sectional microstructural alterations in patients relative to controls. Keywords: Spinocerebellar ataxia, Imaging biomarkers, Apparent fiber density, Fixel analysis, Diffusion imaging.http://www.sciencedirect.com/science/article/pii/S2213158218301943